1/1
Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate‑to‑Severe Atopic Dermatitis Over a 32‑Week Period: An ECZTRA 3 Post Hoc Analysis
Version 5 2022-09-05, 01:11
Version 4 2022-08-16, 20:56
Version 3 2022-08-16, 20:47
Version 2 2022-08-16, 20:46
Version 1 2022-07-06, 20:09
media
posted on 2022-09-05, 01:11 authored by Adis Journals on behalf of:, Jonathan I. Silverberg, David N. Adam, Matthew Zirwas, Sunil Kalia, Jan Gutermuth, Andreas Pinter, Andrew E. Pink, Andrea Chiricozzi, Sebastien Barbarot, Thomas Mark, Ann‑Marie Tindberg, Stephan WeidingerArticle full text
The above digital features represent the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).
© The authors, CC-BY-NC 2022.
